Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.

Stories

Reality check on Lilly's new, cheaper insulin

An Eli Lilly insulin manufacturing facility in France.
An Eli Lilly insulin manufacturing facility in France. Photo: Frederick Florina/AFP/Getty Images

Eli Lilly’s decision to start selling a new version of its most popular fast-acting insulin highlights the industry’s concerns about possible legislation or regulation to rein in drug prices.

Reality check: Some diabetic patients will benefit from Lilly's new authorized generic, called Lispro. But the PR-heavy move, which has been replicated for other controversially priced medicines, isn't structural change. It aligns with the Trump administration's goal of lowering prices at the pharmacy counter — not necessarily what the system overall pays.

By the numbers: Humalog, which generated $3 billion of revenue for Lilly in 2018, has a list price of $275 per vial. Lispro’s list price will be half that.

Yes, but: A Lilly spokesperson confirmed that Lispro's price will be "comparable" to what Humalog costs after accounting for rebates and discounts.

  • There's no guarantee health insurers or pharmacy benefit managers will cover Lispro, and it's highly unlikely Lilly will offer sizable rebates, if any, for this insulin product.
  • A spokesperson said the company is "not able to comment or speculate on what the rebates will be."

We’ve seen this movie before.

  • Mylan created an authorized generic for its EpiPens in 2016.
  • Gilead created authorized generics for its hepatitis C medications last year.
  • Releasing authorized generics allows companies to compete with themselves, which benefits them more than cutting the price of the brand-name drug.

The bottom line: Lilly's generic insulin will help people with diabetes who don't have insurance, or who face high deductibles and coinsurance rates.

  • But it will not fundamentally change what the country pays for this kind of insulin — or others versions of insulin.
  • Patient advocates who have diabetes pointed out that at $140 per vial, Lispro will still cost 7 times as much as the same insulin in other developed countries.

Go deeper: Axios' special report on drug pricing

More stories loading.